JA LSJ OIMT GARTNER_Final.pdf

General Services Administration Federal Supply Schedule Limited Source Justification

RFP #1243024

1. Identification of the agency and contracting activity:

a. Federal agency and contracting activity.

Off ice of Acquisition and Grant Services (OAGS) U.S. Food and Drug Administration (FDA) U.S. Department of Health and Human Services (HHS)

b. Sponsoring organization.

Off ice of Information and Management and Technology (OIMT) FDA Office of Operations (OO)

c. Contracting Officer’s Representative (COR)/Requiring Activity Point of Contact (POC) information.

i. Name: Mahesh Choksi

ii. Mailing address: 11601 Landsdown St, 3WFN, North Bethesda, MD 20857

iii. Email address: Mahesh Choksi@fda.hhs.gov

iv. Telephone number: 301Ͳ796Ͳ7844

2. Nature and/or description of the action being approved.

Gartner, Inc. Consulting Services

a. Acquisition purpose and objectives.

The purpose of the acquisition is to obtain Gartner consulting services to analyze the Office of Information Management and Technology’s acquisition capabilities and provide recommendations to improve the process. This includes conducting an acquisition assessment; develop an acquisition roadmap that would to optimize OIMT contract portfolio;

and provide recommendations that will allow OIMT to optimize its Information Technology (IT) investments through procurement management techniques.

b. Project background.

OIMT is embarking on an acquisition improvement initiative to determine how to revamp its acquisition management practices. OIMT is seeking assistance to reframe how its currently conducting IT procurements and vendor management to ensure they are aligned to industry best practices. The goal of the initiative is to ensure OIMT can leverage existing and future vendor partnerships; incorporate best-in-class contracting techniques into the IT acquisition process so OIMT can meet mission objectives; implement practices that will foster long lasting vendor partnerships; increase organizational performance; and improve contract execution.

mailto:Choksi@fda.hhs.gov

Last Modified: April 5, 2017 Page 2 of 6

OIMT will executes approximately 455 acquisitions valued at approximately $606M in FY21.

This represents 45% of total annual FDA IT spend, while the remaining IT dollars are managed and spent autonomously within FDA centers. A significant number of these contracts actions are procured in a siloed manner; resulting in the multiple procurements actions acquiring the same products and services; and do not allow FDA to leverage its purchasing power. One of OIMT primary challenges is to deliver efficient vendor management in this complex environment.

OMIT is currently a Level I on the Capability Maturity Model as it pertains to acquisition and vendor management. OIMT’s goals is to obtain Level III within the next 18-24 months.

3. Description of the supplies or services required to meet the agency’s needs (including the estimated value).

a. Project title.

IT Contract Optimization Assessment Advisory Services

b. Project Description.

The IT technical and business market environment is extremely dynamic and is in constant change. OIMT requires assistance in analyzing its IT contract portfolio, contract processes, and tools it uses to manage vendors so it can become agile and be able to take advantage of a rapidly changing technological environment to ensure that FDA can meets its evolving mission sets and support both its internal and external customers. OIMIT needs to apply industry standards, frameworks, methodologies, approaches, concepts, best practices based on industry data. The project goals are as follows:

x Contract Consolidation: Identify contracts that can be consolidated taking into consideration FDA’s socio-economic goals and reduce the overall contract actions by 20%.

x Identify Costs Savings: Identify 10%-20% of short-term and long-term contract cost savings opportunities by leverage FDA purchasing power.

x Standardize Procurement and Vendor Management Processes: Develop and implement industry-based procurement and vendor management processes to improve contract performance and allow OIMT to become more agile and responsive to the FDA Centers.

Requirement type.

□ Research & Development (R&D)

□ R&D support services

X Support services (non R&D)

□ Supplies/equipment

X Information Technology (IT)

□ Construction

□ Architect Engineer (A&E) services

□ Design build

□ Other:

Last Modified: April 5, 2017 Page 3 of 6

Type of action.

xNew requirement

□ Follow-on

□ Other:

Proposed contract/order type.

X Firm fixed price

□ Other fixed price:

□ Cost plus fixed fee x Other cost reimbursement: Fixed Price Incentive Fee

□ Time and materials

□ Indefinite delivery:

□ Other:

□ Completion Form

□ Term Form

Acquisition identification number.

RFP #1243024

c. Total estimated dollar value and performance/delivery period.

Estimated Price: $750,000.00 Period of Performance: 12 months

4. Identification of the statutory authority permitting other than full and open competition. Check the applicable block below based on the acquisition circumstance.

Federal Acquisition Regulation (FAR):

x 6.302-1 Only one responsible source and no other supplies or services will satisfy agency requirements. This acquisition is conducted under the authority of United States Code (U.S.C.) 10 U.S.C. 2304(c)(1) or 41 U.S.C. 3304(a)(1).

☐ 6.302-2 Unusual and compelling urgency. This acquisition is conducted under the authority of United States Code (U.S.C.) 10 U.S.C. 2304(c)(2) or 41 U.S.C. 3304(a)(2).

☐ 6.302-3 Industrial mobilization; engineering, developmental, or research capability; or expert services. This acquisition is conducted under the authority of United States Code (U.S.C.) 10 U.S.C. 2304(c)(3) or 41 U.S.C. 3304(a)(3).

☐ 6.302-4 International agreement. This acquisition is conducted under the authority of United States Code (U.S.C.) 10 U.S.C. 2304(c)(4) or 41 U.S.C. 3304(a)(4).

☐ 6.302-5 Authorized or required by statute. This acquisition is conducted under the

Last Modified: April 5, 2017 Page 4 of 6 authority of United States Code (U.S.C.) 10 U.S.C. 2304(c)(5) or 41 U.S.C. 3304(a)(5).

☐ 6.302-6 National security. This acquisition is conducted under the authority of United States Code (U.S.C.) 10 U.S.C. 2304(c)(6) or 41 U.S.C. 3304(a)(6).

☐ 6.302-7 Public interest. This acquisition is conducted under the authority of United States Code (U.S.C.) 10 U.S.C. 2304(c)(7) or 41 U.S.C. 3304(a)(7).

☐ 13.501(a)(1)(ii) Sole source, including brand name, under Simplified Procedures for Certain Commercial Items. This acquisition is using this justification format, modified to reflect that the procedures in FAR subpart 13.5 were used in accordance with 41 U.S.C.

1901 or the authority of 41 U.S.C. 1903.

5. Demonstration that the proposed contractor(s) unique qualifications or the nature of the acquisition requires use of the authority cited.

a. Name and address of the proposed contractor(s).

Gartner, Inc.

1201 Wilson Blvd Arlington, VA 22209

b. Nature of the acquisition and proposed unique qualifications of the contractor(s).

Gartner has a long history assisting Federal agencies and corporation in optimizing their IT portfolios and vendor management relationships. It also is very knowledgeable as it pertains to the laws and regulations governing Federal IT investments. OIMT intends to leverage Gartner’s expertise in these areas.

Gartner already has a high-level understanding of the OIMT organization and how it can apply its various frameworks and industry data to the challenges facing OIMT faces as it pertains to its existing IT acquisition capabilities. OIMT is examining how to best procure IT hardware, software, and services to meet the evolving IT needs of FDA. OIMT is trying to determine how to: (1) optimize its contract portfolio from a cost perspective; (2) how it to optimize its existing workforce to ensure they possess the right skills and competencies; (3) how to ensure that the acquire IT is delivered in the most cost-effective manner; (4) FDA/OIMIT is receiving maximum value as it pertains to its IT investments; and (5) is it effectively leveraging external services and contractors to support the agency’s IT requirements?

Gartner possess a range of proprietary assessment tools, IT market information, benchmark data, and industry understanding that can be applied to OIMT’s acquisition management challenges.

These include its Contract Score & Talent Score tool and key IT Metrics Data. Gartner’s benchmarking capability is based on more than 2,000 IT metrics drawn from 7,280 data points from the public and private sectors. FDA will have access to these tools to perform iterative benchmarking assessments and track progress against recommendations and maturity models developed during the more comprehensive assessment by Gartner Consulting. The objective is to develop a detailed assessment and roadmap for implementing the appropriate contract optimization and IT Asset management recommendations.

Last Modified: April 5, 2017 Page 5 of 6

6. Description of efforts made to ensure that offers are solicited from as many potential sources as is practicable, including whether a notice was or will be publicized as required by subpart 5.2 and, if not, which exception under 5.202 applies.

This initiative is a one-time order. Any resulting recommendations f rom this initiative will be reviewed and assessed to determine if other vendors could perform the new work. If the determination is made that other vendors can perform any follow-on actions, it will be competed among those vendors

7. Determination by the Contracting Officer that the anticipated cost/price to the Government will be fair and reasonable.

The Contracting Officer will utilize the Contractor’s GSA contract to determine price reasonableness.

8. Description of the market research conducted (see FAR Part 10) and the results, or a statement of the reasons market research was not conducted.

OIMT reviewed GSA’s vendor lists and conducted company website searches to determine if other vendors possessed the analysis tools and benchmark data as it pertains contracts, labor categories, processes, and industry best practices. OIMT could not identify any other vendors who possessed the robust tool sets and benchmark data that Gartner possesses.

9. Any other facts supporting the use of other than full and open competition.

Gartner Consulting is an extension of Gartner Research, the free flow of knowledge between Gartner Research and Consulting ensures Gartner Consulting access to background information and context necessary to support FDA expansion efforts on recommendations generated by Gartner Research.

Any other company would need a minimum of six months to obtain the same level of FDA-specific expertise and knowledge. This ramp-up period could put FDA at risk of not being able to fully identify and implement changes sought by the Executive Leadership. It is unacceptable to place this significant initiative at risk of unnecessary delay or failure.

10. Listing of sources, if any, that expressed, in writing, an interest in the acquisition.

No other sources have expressed an interest, in writing, in the proposed acquisition.

11. Statement of the actions, if any, the agency may take to remove or overcome any barriers to competition before any subsequent acquisition for the required supplies or services.

None.

12. Program office certification.

This is to certify that the portions of this justification that have been developed by the undersigned program office personnel, including supporting information and/or data verifying the Government’s minimum needs, schedule requirements and other rationale for other than full and open competition, are accurate and complete.

Last Modified: April 5, 2017 Page 6 of 6

Signature:

Mahesh Choksi COR/Requiring Activity POC

13. Contracting Officer Certification.

This is to certify that the justification for the proposed acquisition has been reviewed and that to the best of my knowledge and belief the information and/or data provided to support the rationale and recommendation for approval is accurate and complete.

Signature:

Phillip Frame Contracting Officer

14. Division Director and Head of the Contracting Activity signature(s).

Signature:__________________________________

Andrew Jernell Division Director

Mahesh K.

Choksi -S

Digitally signed by Mahesh K. Choksi -S Date: 2021.09.05 22:53:15 -04'00'